The abstract is read at the publisher; the summary is JClub's.
Lymphatic filariasis-associated lymphedema affects an estimated 120 million people, with over 40 million living with irreversible limb or genital disfigurement and lifelong disability.
- Why it matters: Transmission control has reduced infection, but people with established lymphatic filariasis-associated lymphedema remain largely neglected because current care cannot stage or reverse established lymphatic failure.
- What they did: This review synthesizes evidence on immunopathogenesis, emphasizing sustained host-parasite interactions, chronic inflammation, immune dysregulation, microbial persistence, and lymphatic tissue remodeling, and discusses emerging biomarkers and targets.
- The result: Stage-specific diagnostics and mechanism-informed interventions are highlighted as essential to improve quality of life and enable meaningful, sustainable elimination of lymphatic filariasis-associated morbidity.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.